January 2019

Expert perspectives on improving cognitive measures from clinical trials to clinical practice.

Cogstate Tests Show No Cognitive Impairment from Use of Lorlatinib for the Treatment of Non-Small-Cell Lung Cancer

January 16, 2019

During the drug development process, it’s important to characterize the nature and magnitude of any adverse effects a drug may have on cognition, even if the underlying disease is not brain-related. However, many Phase 1 and Phase 2 clinical trials do not incorporate objective, performance-based cognitive measurement tools as part of their safety assessment. Cognitive […]